NovaBay Pharmaceuticals stock jumps 102% — what to watch for NBY before Monday

NovaBay Pharmaceuticals stock jumps 102% — what to watch for NBY before Monday

New York, January 11, 2026, 07:38 EST — The market has closed.

Shares of NovaBay Pharmaceuticals, Inc (NBY) soared Friday, closing up 102.5% at $19.16. The NYSE American stock will remain in focus when U.S. markets reopen Monday. (Daily Times Leader)

Friday’s session ended a wild ride for the microcap, with shares bouncing between $9.69 and $19.95. Trading volume surged to roughly 10 million shares, a big jump from around 1.3 million the day before, according to stock data. (StockAnalysis)

Why it matters now: investors are digging into older filings for signs of potential dilution — when new shares or similar securities hit the market, existing shareholders end up with a smaller piece of the pie. One filing outlined pre-funded warrants, which act like almost fully paid options to buy stock, set to become exercisable after Jan. 1, 2026, pending shareholder approval. (SEC)

In an August filing, the company revealed it chose to follow a strategic investment route instead of moving forward with its earlier approved liquidation plan. NovaBay noted that the preferred stock sold in that financing, once converted, would account for over 90% of the common stock on a fully diluted basis.

David E. Lazar, the investor behind the deal, stepped in as CEO. “In making this significant investment in NovaBay, I look forward to maintaining NovaBay’s public listing,” Lazar said at the time. (GlobeNewswire)

In October, NovaBay announced it had met the NYSE American’s minimum stockholders’ equity requirements again, following fundraising through pre-funded warrants and Series E non-voting convertible preferred stock. The company confirmed the exchange had verified the equity-related deficiencies were cleared. (GlobeNewswire)

NovaBay makes and markets eyecare and wound-care products, including Avenova, an antimicrobial solution for lids and lashes, and PhaseOne, a skin and wound cleanser based on hypochlorous acid, the company states. (NovaBay Investors)

Friday’s session saw the Dow climb while the Nasdaq Composite dipped, leaving the market mixed. That kind of environment tends to hit small, volatile stocks hardest, since they often move on shifts in risk appetite rather than underlying fundamentals. (Nasdaq)

That same capital structure that kept NovaBay on the exchange could complicate things for shareholders in the short term. If additional securities convert or get exercised, the share count could spike fast, putting downward pressure on the stock. With thin trading volumes, the price swings can be sharp and unpredictable.

This week, traders are watching closely for new filings on share issuance, conversion approvals, or updates on transactions. A major macro event is the U.S. Consumer Price Index report for December 2025, scheduled for release Jan. 13 at 8:30 a.m. Eastern Time. (Bls)

Stock Market Today

  • Profound Medical: Top TSX Growth Stock Poised for Rapid Expansion, Q3 Revenues Surge 87%
    February 1, 2026, 9:22 PM EST. Profound Medical (TSX:PRN), a Canadian medical device firm specializing in MRI-guided ultrasound therapies, is highlighted as the sole TSX growth stock to hold for the next three years. The company reported an 87% revenue increase in Q3 to $5.3 million, driven by expanded installations of its flagship TULSA-PRO prostate cancer treatment system. Offering incision-free, MRI-guided ablation technology, Profound's procedures have gained Medicare approval with rising insurance reimbursements. Despite a net loss of $8 million, the company improved gross margins to 74.3% and ended Q3 with $25 million cash, supporting near-term liquidity. With 70 systems installed and 93 in advanced sales stages, Profound aims for 75 installations by year-end, making it a notable small-cap growth stock in healthcare on the TSX.
Applied Digital (APLD) stock jumps 18%: hyperscaler lease talks and new financing set the stakes for Monday
Previous Story

Applied Digital (APLD) stock jumps 18%: hyperscaler lease talks and new financing set the stakes for Monday

CG Oncology stock (CGON) jumps 29% on faster PIVOT-006 Phase 3 readout — what to watch next
Next Story

CG Oncology stock (CGON) jumps 29% on faster PIVOT-006 Phase 3 readout — what to watch next

Go toTop